Compare Davita Inc (DVA) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Innodata Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Innodata Inc trades at $62.05 (market cap $2.18B). The key difference: Davita Inc is far larger — about 5.2× Innodata Inc's market cap, and Davita Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Innodata Inc for 19 Days on average.
| DVA | INOD | |
|---|---|---|
Market Cap | $11.28B | $2.18B |
Volume | 650,294 | 1,415,262 |
Sector | Health | Technology |
52-Week High | $240.96 | $121.50 |
52-Week Low | $103.87 | $34.45 |
Typical Hold Time | 113 Days | 19 Days |
Enterprise Value | $24.00B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
INOD trades at $63.42, down 4.26% today, but maintains strong technical support near $63. The company demonstrates robust fundamentals with revenue growing from $252M in 2025 to $317M in 2026 and net income expanding from $32M to $46M. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.42 surpassing the $0.13 estimate. Analyst sentiment remains positive with a 66.7% buy rating consensus.
INOD presents growth potential through its AI data engineering services and new motion-capture lab expansion, though premium valuation metrics (P/E 49.12, P/S 6.91) and customer concentration risks warrant caution. The stock's technical positioning near key support levels combined with strong earnings momentum supports a constructive outlook for investors seeking AI infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
